2023 World Conference on Lung Cancer (Posters)-P2.09. Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer

P2.09. Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

A retrospective study was conducted to assess the efficacy and safety of aumolertinib as second- and third-line therapy in patients with non-small cell lung cancer (NSCLC) who were negative or had unknown status for the EGFR T790M mutation. The study enrolled 31 patients between April 2020 and October 2022 at Beijing Cancer Hospital. <br />For patients who received second-line aumolertinib treatment, the median progression-free survival (mPFS) was 11.3 months, with an overall response rate (ORR) of 12% and disease control rate (DCR) of 82%. In the subgroup of patients with brain metastases, the mPFS was 10.6 months, with an ORR of 25% and DCR of 88%. <br />For patients who received third-line aumolertinib treatment, the mPFS was 6.3 months, with an ORR of 0% and DCR of 79%. The study also reported manageable toxicity, with rash and diarrhea observed in 12.9% and 16.1% of patients, respectively. Grade 3 or higher adverse events were not observed. <br />The study concluded that aumolertinib showed promising antitumor activity and manageable toxicity as second- and third-line therapy in EGFR T790M-negative/unknown NSCLC, both with and without brain metastases. The results suggest that aumolertinib could be a potential treatment option for these patients who have limited targeted therapy options. The study did not identify any conflicts of interest, and no new safety signals were observed.

Asset Subtitle

Jieran Long

Meta Tag

Speaker Jieran Long

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

retrospective study

aumolertinib

second-line therapy

third-line therapy

NSCLC

EGFR T790M mutation

progression-free survival

toxicity

brain metastases

targeted therapy options